| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T317 |
0-119 |
Sentence |
denotes |
We found pharmacological inhibitors of CK2, p38 MAPK signaling, PIKFYVE, and CDKs to possess strong antiviral efficacy. |
| T318 |
120-331 |
Sentence |
denotes |
Cells were pre-treated with inhibitor molecules, followed by SARS-CoV-2 infection (STAR Methods), and virus quantity (anti-NP antibody against SARS-CoV-2) and cell viability were quantified 48 h after infection. |
| T319 |
332-525 |
Sentence |
denotes |
As a positive control and for comparison, remdesivir was tested, and the expected favorable antiviral activity was observed (half maximal inhibitory concentration [IC50 ] = 1.28 μM; Figure 7B). |
| T320 |
526-654 |
Sentence |
denotes |
Silmitasertib, an inhibitor of CSNK2A1 and CSNK2A2, was found to possess antiviral activity (IC50 = 2.34 μM; Figures 7C and S5). |
| T321 |
655-952 |
Sentence |
denotes |
In conjunction with data supporting physical interaction (Gordon et al., 2020) and co-localization with N protein (Figure 5F), as well as a potential role in remodeling extracellular matrix upon infection (Figures 5 and S3), CK2 signaling appears to be an important pathway hijacked by SARS-CoV-2. |
| T322 |
953-1066 |
Sentence |
denotes |
Furthermore, silmitasertib is currently being considered for human testing as a potential treatment for COVID-19. |
